Peptide harm reduction: difference between revisions
Diff·revision 22 → 23·18:01, 31 Aug 2025
Difference between revision 22 and revision 23 of Peptide harm reduction. 2 lines changed; the page grew by 170 bytes.
| Revision 22 — 09:17, 12 Aug 2025 StubSorterBot (talk) bot: normalise currency formatting 4,630 bytes ±0 | Revision 23 — 18:01, 31 Aug 2025 PBM_Perrin (talk) de-orphan 4,800 bytes +170 | ||
|---|---|---|---|
| 40 | It gives no dosing guidance, describes no preparation intended for administration, and does not evaluate suppliers for suitability. Where handling is described — at [[Reconstitution of lyophilised peptides]], for instance — it is described mechanistically, and the register is deliberately descriptive. | 40 | It gives no dosing guidance, describes no preparation intended for administration, and does not evaluate suppliers for suitability. Where handling is described — at [[Reconstitution of lyophilised peptides]], for instance — it is described mechanistically, and the register is deliberately descriptive. |
| 41 | 41 | ||
| + | 42 | Nothing on this wiki is medical advice. Research-use compounds are not approved for human use, and this article does not represent them as suitable for it.{{r|usp1503}} | |
| + | 43 | ||
| 42 | == References == | 44 | == References == |
| 43 | {{reflist}} | 45 | {{reflist}} |